• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

作者信息

Stessman H A F, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers C L, Van Ness B G, Dolloff N G

机构信息

Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA.

Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.

出版信息

Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9.

DOI:10.1038/leu.2014.214
PMID:25005244
Abstract
摘要

相似文献

1
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.高通量药物筛选可识别针对蛋白酶体抑制剂耐药性多发性骨髓瘤的化合物和分子策略。
Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9.
2
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.药物基因组学 RNAi 筛选鉴定多发性骨髓瘤蛋白酶体抑制剂敏感性的调节剂，包括 CDK5。
Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.
3
Innovation in myeloma treatments PARP excellence!骨髓瘤治疗领域的创新 PARP卓越！
Blood. 2011 Dec 8;118(24):6234-5. doi: 10.1182/blood-2011-10-381129.
4
Effect of noncompetitive proteasome inhibition on bortezomib resistance.非竞争性蛋白酶体抑制对硼替佐米耐药性的影响。
J Natl Cancer Inst. 2010 Jul 21;102(14):1069-82. doi: 10.1093/jnci/djq198. Epub 2010 May 26.
5
Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.通过咪唑烷骨架对蛋白酶体的非竞争性调节克服硼替佐米耐药性并延缓体内 MM 肿瘤生长。
ACS Chem Biol. 2013 Mar 15;8(3):578-87. doi: 10.1021/cb300568r. Epub 2012 Dec 11.
6
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.硼替佐米耐药骨髓瘤细胞系与 PSMβ5 过表达和多倍体有关。
Leuk Res. 2012 Feb;36(2):212-8. doi: 10.1016/j.leukres.2011.09.011. Epub 2011 Oct 5.
7
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.靶向线粒体以克服多发性骨髓瘤（MM）细胞中的传统耐药性及硼替佐米/蛋白酶体抑制剂PS-341耐药性。
Blood. 2004 Oct 15;104(8):2458-66. doi: 10.1182/blood-2004-02-0547. Epub 2004 Jun 24.
8
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.MiR-29b替代抑制蛋白酶体并破坏聚集体+自噬体形成，以增强硼替佐米的抗骨髓瘤疗效。
Leukemia. 2015 Mar;29(3):727-38. doi: 10.1038/leu.2014.279. Epub 2014 Sep 19.
9
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.临床环境中的蛋白酶体抑制剂：克服多发性骨髓瘤对蛋白酶体抑制剂耐药性的益处和策略。
Drugs R D. 2007;8(1):1-12. doi: 10.2165/00126839-200708010-00001.
10
Discovery and development of second-generation proteasome inhibitors.第二代蛋白酶体抑制剂的发现和研发。
Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007.

引用本文的文献

1
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.多发性骨髓瘤获得硼替佐米耐药：从机制到策略。
Curr Treat Options Oncol. 2024 Nov;25(11):1354-1365. doi: 10.1007/s11864-024-01273-6. Epub 2024 Oct 21.
2
ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.ATF3 协调表观遗传药物与蛋白二硫键异构酶抑制剂的抗肿瘤协同作用。
Cancer Res. 2020 Aug 15;80(16):3279-3291. doi: 10.1158/0008-5472.CAN-19-4046. Epub 2020 Jun 19.
3
Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research.

本文引用的文献

1
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.在骨髓瘤小鼠模型中，CXCR4表达降低与髓外疾病相关，并预示接受硼替佐米治疗的多发性骨髓瘤患者生存期较差。
Leukemia. 2013 Oct;27(10):2075-7. doi: 10.1038/leu.2013.148. Epub 2013 May 14.
2
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.对硼替佐米耐药进行分析鉴定了小鼠骨髓瘤模型中的二线治疗药物。
Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.
3
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
针对多发性骨髓瘤浆细胞应激抗性/恢复力的可行策略：“组学”研究的见解
Front Oncol. 2020 May 15;10:802. doi: 10.3389/fonc.2020.00802. eCollection 2020.
4
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.用新型烯丙基茚满 PD1 抑制剂调节异构体选择性和硼替佐米敏感性。
Eur J Med Chem. 2020 Jan 15;186:111906. doi: 10.1016/j.ejmech.2019.111906. Epub 2019 Nov 21.
5
Discovery platform for inhibitors of IgH gene enhancer activity.IgH 基因增强子活性抑制剂的发现平台。
Cancer Biol Ther. 2019;20(4):571-581. doi: 10.1080/15384047.2018.1538615. Epub 2018 Nov 27.
6
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.一种基因表达特征可区分多发性骨髓瘤中对蛋白酶体抑制剂的天然反应和抗性。
Blood Cancer J. 2017 Jun 30;7(6):e581. doi: 10.1038/bcj.2017.56.
7
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.癌症“组学”时代克服多发性骨髓瘤耐药性
Leuk Lymphoma. 2018 Mar;59(3):542-561. doi: 10.1080/10428194.2017.1337115. Epub 2017 Jun 13.
8
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.谷氨酰胺酶抑制剂CB-839与卡非佐米在耐药多发性骨髓瘤细胞中具有协同作用。
Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.
9
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.单细胞分析靶向转录组预测人骨髓瘤肿瘤内单细胞的药物敏感性。
Leukemia. 2016 May;30(5):1094-102. doi: 10.1038/leu.2015.361. Epub 2015 Dec 29.
蛋白酶体β5 亚基突变导致硼替佐米结合能力受损是白血病细胞硼替佐米耐药的基础。
Leukemia. 2012 Apr;26(4):757-68. doi: 10.1038/leu.2011.256. Epub 2011 Sep 23.
4
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.MDM2 拮抗剂 Nutlin-3 增强了硼替佐米介导的 TP53 突变套细胞淋巴瘤中线粒体凋亡。
Cancer Lett. 2010 Dec 28;299(2):161-70. doi: 10.1016/j.canlet.2010.08.015. Epub 2010 Sep 17.
5
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.MDM2 拮抗剂 nutlin 联合蛋白酶体抑制剂 velcade 联合具有协同的抗骨髓瘤活性。
Cancer Biol Ther. 2010 Jun 1;9(11):936-44. doi: 10.4161/cbt.9.11.11882. Epub 2010 Jun 27.
6
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.Hdm2/p53 通路与蛋白酶体通路的相互作用可能增强硼替佐米的抗肿瘤活性。
Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24.
7
Proteasome inhibitors in the treatment of multiple myeloma.蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用
Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10.
8
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.蛋白酶体抑制剂诱导多发性骨髓瘤多药耐药表型的产生
Leukemia. 2009 Nov;23(11):2181-3. doi: 10.1038/leu.2009.123. Epub 2009 Jun 11.
9
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.硼替佐米适应细胞中泛素-蛋白酶体系统的特征分析
Leukemia. 2009 Jun;23(6):1098-105. doi: 10.1038/leu.2009.8. Epub 2009 Feb 19.
10
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.通过MDM2小分子拮抗剂在体内激活p53通路。
Science. 2004 Feb 6;303(5659):844-8. doi: 10.1126/science.1092472. Epub 2004 Jan 2.